InMed Pharmaceuticals (INM) Other Non-Current Assets (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Other Non-Current Assets of $104368.0 for Q1 2026, up 4.37% year-over-year from $100000.0 in Q1 2025, and up 4.37% quarter-over-quarter from $100000.0 in Q4 2025.
InMed Pharmaceuticals (INM) Other Non-Current Assets (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $104368.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 4.37% year-over-year to $104368.0; the TTM figure through Mar 2026 stood at $104368.0 (up 4.37% YoY), while the FY2025 annual figure was $100000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $104368.0, up from $100000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $176637.0 in Q2 2022, with the low at $100000.0 in Q4 2023.
- The 5-year median for Other Non-Current Assets is $100000.0 (2023), against an average of $116828.1.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets surged 1884.12% in 2022, then tumbled 41.56% in 2023.
- InMed Pharmaceuticals' Other Non-Current Assets stood at $171130.0 in 2022, then sank by 41.56% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then climbed by 4.37% to $104368.0 in 2026.
- Business Quant data shows INM's Other Non-Current Assets at $104368.0 in Q1 2026, $100000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | InMed Pharmaceuticals | 6.44 Mn | 1.20 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 104,368.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 101,790.00 |
| Jun 30, 2023 | 104,908.00 |
| Mar 31, 2023 | 147,489.00 |
| Dec 31, 2022 | 171,130.00 |
| Sep 30, 2022 | 171,130.00 |
| Jun 30, 2022 | 176,637.00 |
| Mar 31, 2022 | 108,625.00 |
| Dec 31, 2021 | 109,175.00 |
| Sep 30, 2021 | 8,625.00 |
| Jun 30, 2021 | 14,655.00 |